Abstract
Background-: Dabigatran 150 and 110 mg twice a day and warfarin are effective for stroke prevention in atrial fibrillation. The purpose of this study was to compare their risks of bleeding in the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial. Methods and results-: The RE-LY trial randomized 18 113 patients to receive dabigatran 110 or 150 mg twice a day or warfarin dose adjusted to an international normalized ratio of 2.0 to 3.0 for a median follow-up of 2.0 years. Compared with warfarin, dabigatran 110 mg twice a day was associated with a lower risk of major bleeding (2.87% versus 3.57%; P=0.002), whereas dabigatran 150 mg twice a day was associated with a similar risk of major bleeding (3.31% versus 3.57%; P=0.32). There was a significant treatment-by-age interaction, such that dabigatran 110 mg twice a day compared with warfarin was associated with a lower risk of major bleeding in patients aged
| Original language | English |
|---|---|
| Pages (from-to) | 2363-2372 |
| Number of pages | 10 |
| Journal | Circulation |
| Volume | 123 |
| Issue number | 21 |
| DOIs | |
| Publication status | Published - May 31 2011 |
Fingerprint
Keywords
- anticoagulants
- atrial fibrillation
ASJC Scopus subject areas
- Physiology (medical)
- Cardiology and Cardiovascular Medicine
Cite this
Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation : An analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) Trial. / Eikelboom, John W.; Wallentin, Lars; Connolly, Stuart J.; Ezekowitz, Mike; Healey, Jeff S.; Oldgren, Jonas; Yang, Sean; Alings, Marco; Kaatz, Scott; Hohnloser, Stefan H.; Diener, Hans Christoph; Franzosi, Maria Grazia; Huber, Kurt; Reilly, Paul; Varrone, Jeanne; Yusuf, Salim.
In: Circulation, Vol. 123, No. 21, 31.05.2011, p. 2363-2372.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation
T2 - An analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) Trial
AU - Eikelboom, John W.
AU - Wallentin, Lars
AU - Connolly, Stuart J.
AU - Ezekowitz, Mike
AU - Healey, Jeff S.
AU - Oldgren, Jonas
AU - Yang, Sean
AU - Alings, Marco
AU - Kaatz, Scott
AU - Hohnloser, Stefan H.
AU - Diener, Hans Christoph
AU - Franzosi, Maria Grazia
AU - Huber, Kurt
AU - Reilly, Paul
AU - Varrone, Jeanne
AU - Yusuf, Salim
PY - 2011/5/31
Y1 - 2011/5/31
N2 - Background-: Dabigatran 150 and 110 mg twice a day and warfarin are effective for stroke prevention in atrial fibrillation. The purpose of this study was to compare their risks of bleeding in the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial. Methods and results-: The RE-LY trial randomized 18 113 patients to receive dabigatran 110 or 150 mg twice a day or warfarin dose adjusted to an international normalized ratio of 2.0 to 3.0 for a median follow-up of 2.0 years. Compared with warfarin, dabigatran 110 mg twice a day was associated with a lower risk of major bleeding (2.87% versus 3.57%; P=0.002), whereas dabigatran 150 mg twice a day was associated with a similar risk of major bleeding (3.31% versus 3.57%; P=0.32). There was a significant treatment-by-age interaction, such that dabigatran 110 mg twice a day compared with warfarin was associated with a lower risk of major bleeding in patients aged
AB - Background-: Dabigatran 150 and 110 mg twice a day and warfarin are effective for stroke prevention in atrial fibrillation. The purpose of this study was to compare their risks of bleeding in the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial. Methods and results-: The RE-LY trial randomized 18 113 patients to receive dabigatran 110 or 150 mg twice a day or warfarin dose adjusted to an international normalized ratio of 2.0 to 3.0 for a median follow-up of 2.0 years. Compared with warfarin, dabigatran 110 mg twice a day was associated with a lower risk of major bleeding (2.87% versus 3.57%; P=0.002), whereas dabigatran 150 mg twice a day was associated with a similar risk of major bleeding (3.31% versus 3.57%; P=0.32). There was a significant treatment-by-age interaction, such that dabigatran 110 mg twice a day compared with warfarin was associated with a lower risk of major bleeding in patients aged
KW - anticoagulants
KW - atrial fibrillation
UR - http://www.scopus.com/inward/record.url?scp=79958126202&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79958126202&partnerID=8YFLogxK
U2 - 10.1161/CIRCULATIONAHA.110.004747
DO - 10.1161/CIRCULATIONAHA.110.004747
M3 - Article
C2 - 21576658
AN - SCOPUS:79958126202
VL - 123
SP - 2363
EP - 2372
JO - Circulation
JF - Circulation
SN - 0009-7322
IS - 21
ER -